



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 12 Dec 2019 (#41)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices & News

- **Updated Grant Application Instructions and Forms Coming in Autumn (US Spring) 2020.** NIH will require the use of updated application forms and instructions (FORMS-F) for due dates on or after May 25, 2020 ([NOT-OD-20-026](#)).
- **NIH Needs Your Feedback on a DRAFT NIH Policy for Data Management and Sharing:** NIH has released for public comment a [Draft NIH Policy for Data Management and Sharing](#) along with supplemental draft guidance. Since releasing a [Request for Information](#) last year on Proposed Provisions of a Draft NIH Data Management and Sharing Policy, NIH has received helpful feedback that has been incorporated into this version of the draft policy proposal. The draft policy requires all NIH-funded grantees to submit a Data Management and Sharing Plan outlining how researchers plan to manage scientific data, including when and where the scientific data will be preserved and shared. Plans may include consideration of other factors (e.g., legal, ethical) that may appropriately limit data sharing.
- **Tips Before You Submit:** [Selecting the Correct Budget Format for Your Application](#). Providing budget information is a necessary part of requesting federal funding. Many research grant programs require applicants to choose between two budget formats. When presented with budget format options, you need to carefully read the funding opportunity and application guide instructions and choose the budget format that matches your situation.
- **A Blizzard Ate My Application! What Can I Do?** NIH has a standing [natural disaster policy](#) that can protect you in the event a natural disaster such as a hurricane or blizzard closes your institution close to an application due date. If your institution closes due to an emergency, keeping you from being able to get your application in on time, document the reason in the cover letter of your application. Keep in mind that the delay in the submission should not exceed the time period of your institution's closure. Reasons for late applications are reviewed on a case-by-case basis, and no one at NIH can grant permission in advance for a late application.
- **Findings of Research Misconduct [NOT-OD-20-029](#):** Findings of research misconduct have been made against a Postdoctoral Fellow, Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health (JHSPH) in research supported by U.S. Public Health Service (PHS) funds, specifically National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH). She knowingly, intentionally, and/or recklessly falsified and/or fabricated Western blot data for protein expression in cultured cell lines and/or alveolar macrophages of patients with chronic obstructive pulmonary disease (COPD).
- **Request for Information (RFI) on the 2020 National Institute of Mental Health (NIMH) Strategic Plan for Research:** [NOT-MH-20-003](#)
- **Request for Information (RFI): Increasing the diversity of applications to the NIH Common Fund High-Risk, High-Reward Research Program:** [NOT-RM-20-002](#)
- **Notice of Special Interest: Understanding the Biology of Iodine Nutrition, Assessment, and Outcomes (R01, R21, R03, R43/R44, R41/R42) [NOT-HD-19-039](#):** This Notice will encourage research using a range of disciplines and approaches to address the gaps in our understanding of the biology and functional impact of iodine nutrition, and in particular, mild-to-moderate iodine deficiency in men and women of reproductive age (including women during adolescence, pregnancy, and lactation) as well as in infants and children. Studies across the age spectrum and in various demographic (sex/ethnic/racial) subgroups are of interest as well.

### 1. Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-20-017](#)

**Type:** R21

**Application Due Date:** February 21, 2020; May 28, 2020; September 29, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to fund an estimate of 17 awards, corresponding to a total of \$4,200,000, for fiscal year 2021. Future year amounts will depend on annual appropriations. Direct costs are limited to \$400,000 over a 3-year period, with no more than \$200,000 in direct costs allowed in any single year.

### 2. Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-20-018](#)

**Type:** R33

**Application Due Date:** February 21 2020; May 28, 2020; September 29, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to fund an estimate of 10 awards, corresponding to a total of \$4,300,000, for the fiscal year 2021. Future year amounts will depend on annual appropriations. Direct costs are limited to \$300,000 per year. The total project period request may not exceed 3 years.

### 3. Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-20-019](#)

**Type:** R21

**Application Due Date:** February 21, 2020; May 28, 2020; September 29, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader [Innovative Molecular Analysis Technologies \(IMAT\) Program](#).

**Budget:** NCI intends to fund an estimate of 4 awards, corresponding to a total of \$1,000,000, for the fiscal year 2021. Future year amounts will depend on annual appropriations. Direct costs are limited to \$400,000 over a 3-year period, with no more than \$200,000 in direct costs allowed in any single year. The total project period request may not exceed 3 years.

### 4. Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:**

**Type:** R33

**Application Due Date:** February 21, 2020; May 28, 2020; September 29, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of

highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored [Innovative Molecular Analysis Technologies \(IMAT\) Program](#). Budget: NCI intends to fund an estimate of 2 awards, corresponding to a total of \$900,000, for fiscal year 2021. Future year amounts will depend on annual appropriations. Direct costs are limited to \$300,000 per year. The total project period request may not exceed 3 years.

#### 5. Clinical Trials to Test Artificial Pancreas Device Systems in Populations Challenging to Manage Type 1 Diabetes (T1D) (Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DK-19-036](#)

**Type:** U01

**Application Due Date:** April 09, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This FOA will support the conduct of clinical trials designed to test the clinical safety and efficacy of artificial pancreas (AP) device systems with the objective of improving glycemic control, reducing acute complications and improving quality of life in people with difficult to control T1D when using standard of care therapies.

**Budget:** NIDDK intends to commit \$ 3 million FY 2020 to fund 2-5 awards. Application budgets are limited to a maximum of \$ 1 million direct costs per year. Budgets are expected to reflect the actual needs of the proposed project. The maximum project period is 5 years. The scope of the proposed project should determine the project period.

#### 6. Transformative Technology Development for the Human BioMolecular Atlas Program (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-RM-20-001](#)

**Type:** UG3/UH3

**Application Due Date:** March 3, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues, particularly for characterizing functional modifications, lipids and the extracellular environment. The initial two-year UG3 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for 3D mapping the human body with high resolution.

**Budget:** NIH intends to fund an estimate of 3-5 awards, corresponding to a total of \$1.5 million, for fiscal year 2020. Future year amounts will depend on annual appropriations. Applications must not exceed \$250,000 in direct costs per year during the UG3 phase and \$400,000 in direct costs per year during the UH3 phase. The scope of the proposed project should determine the project period. The proposed project period for the UG3 may not exceed 2 years and the UH3 phase may not exceed 2 years. The total duration of the UG3 and UH3 phases together may not exceed 4 years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizel*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105